Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Beasley, Charles M.; Hamilton, S.H.; Crawford, A.M.; Dellva, Mary Anne; Tollefson, Gary D.; Trân, Pierre V.; Blin, Olivier; Beuzen, J.N.

doi:10.1016/s0924-977x(96)00392-6

Cited by 418 publications

(384 citation statements)

References 19 publications

Supporting

Mentioning

356

Contrasting

Unclassified

Order By: Relevance

“…Beasley et al 1996aBeasley et al , 1996bBeasley et al , 1997Tollefson et al 1997a), this study failed to find differences in clinical ratings between the low dose and high dose of olanzapine. We did not design this study to examine the clinical efficacy of olanzapine and the small sample size and the short duration of treatment preclude any conclusions about clinical efficacy of olanzapine from our data.…”

Section: Discussionmentioning

confidence: 55%

“…In clinical studies olanzapine has proven effective for the treatment of positive and negative symptoms of schizophrenia (Beasley et al 1996a;Beasley et al 1997;Tollefson et al 1997a) with relatively few side effects and minimal EPS (Tollefson et al 1997b;Tran et al 1997). In vitro , olanzapine antagonizes various dopamine, serotonin, histamine, norepinephrine and muscarinic receptors.…”

mentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia

Raedler

Knable

Jones

et al. 2000

Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

mentioning

confidence: 99%

In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia

Raedler

Knable

Jones

et al. 2000

Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…In particular, olanzapine attenuated the increase in locomotion observed after the acute administration of SKF-38393, in contrast to previous findings with clozapine, which did not fully block SKF-38393-induced activity in neonate-lesioned rats, even at a maximal dose of 100 mg/kg (Criswell et al 1989a). It is notable that, although olanzapine and clozapine have been characterized as having comparable effects in behavioral tests (Moore et al 1992(Moore et al , 1997Devaney and Waddington 1996) and similar therapeutic profiles for the treatment of schizophrenia (Beasley et al 1996), radioreceptor binding assays show that olanzapine has a greater affinity for both D 1 -DA and D 2 -DA receptors, but lower affinity for D 4 -DA receptors, in comparison to clozapine (Bymaster et al 1996).…”

Section: Discussionmentioning

confidence: 69%

Effect of Olanzapine on Functional Responses from Sensitized D1-Dopamine Receptors in Rats with Neonatal Dopamine Loss

Moy

Knapp

Breese

2001

Neuropsychopharmacology

View full text Add to dashboard Cite

(Breese et al. 1985a,b). For example, neonate-lesioned animals have increased locomotion following treatment with SKF-38393, a D 1 -DA receptor agonist, at doses that have minimal impact on control rats (Breese et al. 1985a,b). Repeated treatment with D 1 -DA agonists can lead to extremely high rates of activity in lesioned rats, and this "priming" effect can still be observed 6 months after the chronic drug treatment (Breese et al. 1985b;Criswell et al. 1989b). Supersensitivity of D 1 -DA receptors in neonatal-6-OHDA rats has also been linked to stereotyped responses and self-injurious behavior (SIB) following treatment with L-Dopa or apomorphine, suggesting that these animals can provide a valuable model for the self-injury and DA loss associated with Lesch-Nyhan disease (Breese et al. 1984a,b), a metabolic disorder primarily observed in male children (Lesch and Nyhan 1964).Paradoxically, although the aberrant responses in the neonate-lesioned rats can be completely blocked with selective D 1 -DA receptor antagonists (Breese et al. 1985a), these animals are remarkably subsensitive to haloperidol, even at doses which induce catalepsy in normal controls and in rats given 6-OHDA as young adults (Bruno et al. 1985;Duncan et al. 1987). Similarly, treatment with typical antipsychotic agents does not prevent the painful self-injury that occurs in LeschFrom the Departments of Psychiatry (SSM, DJK, GRB), Anesthesiology (GRB) and Pharmacology (GRB), Skipper Bowles Center For

show abstract

“…Antipsychotic drugs commonly used to treat positive symptoms include haloperidol, which has high affinity at the D2 receptor and is considered to be a selective D2 antagonist at clinical doses, and olanzapine, which also displays a high affinity for the D2 receptor as well as binding to 5HT2A receptors at clinical doses (Beasley et al, 1996). Previous reports indicate that selective agents, such as haloperidol, and multireceptor agents, such as olanzapine, may be distinguished by their ability to reverse nonsymptom-based endophenotypes of schizophrenia (Cadenhead and Braff, 2002;Light et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential

Maxwell

Liang

Weightman

et al. 2004

Neuropsychopharmacol

View full text Add to dashboard Cite

Auditory evoked potentials have been used in a variety of animal models to assess information-processing impairments in schizophrenia. Previous mouse models have primarily employed a paired click paradigm to assess the transient measures of auditory gating. The current study uses stimulus trains at varied interstimulus intervals (ISI) between 0.25 and 8 s in mice to assess the effects of chronic olanzapine and haloperidol on auditory processing. Data indicate that olanzapine increases the amplitude of the N40, P80, and P20/N40 components of the auditory evoked potential, whereas haloperidol had no such effect. The ISI paradigm also allowed for an evaluation of several components of the mouse evoked potential to assess those that display response properties similar to the human P50 and N100. Data suggest that the mouse N40 displays an ISI response relationship that shares characteristics with the human N100, whereas the P20 appears more consistent with the human P50 across the ISI range evaluated in this task. This study suggests that olanzapine may help improve N100 impairments seen in schizophrenia, while haloperidol does not.

show abstract

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Cited by 418 publications

References 19 publications

In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia

In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia

Effect of Olanzapine on Functional Responses from Sensitized D1-Dopamine Receptors in Rats with Neonatal Dopamine Loss

Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential

Contact Info

Product

Resources

About